Cardiovascular Systems, Inc. is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company develops an orbital atherectomy technology for both peripheral and coronary commercial applications. Its peripheral artery disease (PAD) systems are catheter-based platforms capable of treating a range of plaque types in leg arteries both above and below the knee. Its products include Diamondback 360 Peripheral Orbital Atherectomy System (OAS) (Diamondback 360 Peripheral), the Stealth 360 OAS (Stealth 360), Diamondback 360 Peripheral, Diamondback 360 60cm Peripheral, Diamondback 360 Low Profile Peripheral, Diamondback 360 1.50 Peripheral and Diamondback 360 2.00 Peripheral. The Company's coronary arterial disease (CAD) product, Diamondback 360 Coronary OAS (Coronary OAS), is marketed as a treatment for severely calcified coronary arteries.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Equipment, Supplies & Distribution
- Sub-Industry: Health Care Equipment
- Symbol: NASDAQ:CSII
- CUSIP: 14161910
- Web: www.csi360.com
Capitalization:- Market Cap: $907.93 million
- Outstanding Shares: 32,991,000
Average Prices:- 50 Day Moving Avg: $29.97
- 200 Day Moving Avg: $30.14
- 52 Week Range: $21.29 - $33.11
P/E:- Trailing P/E Ratio: N/A
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $204.91 million
- Price / Sales: 4.43
- Book Value: $3.60 per share
- Price / Book: 7.64
Profitability:- EBIDTA: $5.43 million
- Net Margins: -0.87%
- Return on Equity: 0.88%
- Return on Assets: 0.58%
Debt:- Debt-to-Equity Ratio: 0.18%
- Current Ratio: 3.88%
- Quick Ratio: 3.47%
Misc:- Average Volume: 242,875 shs.
- Beta: 2.62
- Short Ratio: 4.87
Frequently Asked Questions for Cardiovascular Systems (NASDAQ:CSII)
What is Cardiovascular Systems' stock symbol?
Cardiovascular Systems trades on the NASDAQ under the ticker symbol "CSII."
How were Cardiovascular Systems' earnings last quarter?
Cardiovascular Systems, Inc. (NASDAQ:CSII) posted its quarterly earnings results on Wednesday, August, 2nd. The company reported $0.02 EPS for the quarter, topping the Zacks' consensus estimate of ($0.05) by $0.07. The business earned $52.90 million during the quarter, compared to the consensus estimate of $51.98 million. Cardiovascular Systems had a positive return on equity of 0.88% and a negative net margin of 0.87%. The company's revenue for the quarter was up 9.1% compared to the same quarter last year. During the same period last year, the firm earned ($0.15) earnings per share. View Cardiovascular Systems' Earnings History.
When will Cardiovascular Systems make its next earnings announcement?
Where is Cardiovascular Systems' stock going? Where will Cardiovascular Systems' stock price be in 2017?
8 equities research analysts have issued 12 month price objectives for Cardiovascular Systems' shares. Their predictions range from $30.00 to $40.00. On average, they expect Cardiovascular Systems' share price to reach $34.40 in the next twelve months. View Analyst Ratings for Cardiovascular Systems.
What are analysts saying about Cardiovascular Systems stock?
Here are some recent quotes from research analysts about Cardiovascular Systems stock:
- 1. According to Zacks Investment Research, "Cardiovascular Systems delivered remarkable fourth-quarter 2017 results, with earnings and revenues beating the Zacks Consensus Estimate. The company’s lower operating expenses drove the year-over-year improvement in earnings. Strong revenue performance also contributed to the upside in earnings. Moreover, the improvement in margins is encouraging. Overall, the company’s’ fiscal 2017 performance has been impressive. The company’s fiscal 2018 guidance also instils confidence in investors. It received FDA approval for radial access Diamondback 360 Peripheral Orbital Atherectomy Device. The one-year results from LIBERTY 360 study is to be presented at the 2017 Amputation Prevention Symposium (AMP). In the majority of the last six months, Cardiovascular Systems has been trading above the broader industry. However, the company incurred a net loss of $1.8 million in fiscal 2017. Stiff competition adds to the woes." (8/4/2017)
- 2. Needham & Company LLC analysts commented, "We are reiterating our Buy rating on CSII, raising our FY18 and FY19 estimates, and raising our price target to $37 from $32. Over the next few quarters, we expect revenue growth to slow due to tougher comps but we expect earnings upside to drive shares higher. We expect the ECLIPSE trial and Japan to drive strong coronary growth in coming years." (7/14/2017)
Who are some of Cardiovascular Systems' key competitors?
Some companies that are related to Cardiovascular Systems include MiMedx Group (MDXG), CONMED Corporation (CNMD), OraSure Technologies (OSUR), Asante Solutions (PUMP), K2M Group Holdings (KTWO), Orthofix International N.V. (OFIX), Intersect ENT (XENT), AtriCure (ATRC), CryoLife (CRY), Landauer (LDR), Meridian Bioscience (VIVO), Consort Medical plc (CSRT), Invacare Corporation (IVC), Antares Pharma (ATRS), Exactech (EXAC), STAAR Surgical Company (STAA), Sientra (SIEN) and Utah Medical Products (UTMD).
Who are Cardiovascular Systems' key executives?
Cardiovascular Systems' management team includes the folowing people:
- Scott R. Ward, Chairman of the Board, President, Chief Executive Officer
- Laurence L. Betterley, Chief Financial Officer
- Kevin J. Kenny, Chief Operating Officer
- Sandra Sedo, Chief Compliance Officer
- Alexander Rosenstein, General Counsel and Corporate Secretary
- Martha Goldberg Aronson, Independent Director
- Scott A. Bartos, Independent Director
- Brent G. Blackey, Independent Director
- Edward M. Brown, Independent Director
- William E. Cohn M.D., Independent Director
Who owns Cardiovascular Systems stock?
Cardiovascular Systems' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (5.70%), Frontier Capital Management Co. LLC (2.51%), State Street Corp (2.07%), New York State Common Retirement Fund (1.35%), Northern Trust Corp (1.35%) and First Manhattan Co. (1.29%). Company insiders that own Cardiovascular Systems stock include Alexander Rosenstein, Camber Capital Management Llc, Edward M Brown, Kevin J Kenny, Laura Gillund, Laurence L Betterley, Paul A Koehn, Robert J Thatcher and Scott R Ward. View Institutional Ownership Trends for Cardiovascular Systems.
Who sold Cardiovascular Systems stock? Who is selling Cardiovascular Systems stock?
Cardiovascular Systems' stock was sold by a variety of institutional investors in the last quarter, including First Manhattan Co., Thrivent Financial For Lutherans, Perkins Capital Management Inc., EAM Investors LLC, Wells Fargo & Company MN, Arrowstreet Capital Limited Partnership, Acadian Asset Management LLC and Prudential Financial Inc.. Company insiders that have sold Cardiovascular Systems stock in the last year include Alexander Rosenstein, Edward M Brown, Kevin J Kenny, Laura Gillund, Laurence L Betterley, Paul A Koehn and Scott R Ward. View Insider Buying and Selling for Cardiovascular Systems.
Who bought Cardiovascular Systems stock? Who is buying Cardiovascular Systems stock?
Cardiovascular Systems' stock was purchased by a variety of institutional investors in the last quarter, including New York State Common Retirement Fund, Fred Alger Management Inc., Vanguard Group Inc., Marshall Wace North America L.P., Nationwide Fund Advisors, First Trust Advisors LP, Monarch Partners Asset Management LLC and TIAA CREF Investment Management LLC. Company insiders that have bought Cardiovascular Systems stock in the last two years include Camber Capital Management Llc and Scott R Ward. View Insider Buying and Selling for Cardiovascular Systems.
How do I buy Cardiovascular Systems stock?
Shares of Cardiovascular Systems can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cardiovascular Systems' stock price today?
One share of Cardiovascular Systems stock can currently be purchased for approximately $27.52.
MarketBeat Community Rating for Cardiovascular Systems (NASDAQ CSII)MarketBeat's community ratings are surveys of what our community members think about Cardiovascular Systems and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Cardiovascular Systems (NASDAQ:CSII) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Sell Rating, 2 Hold Ratings, 4 Buy Ratings, 1 Strong Buy Rating |
| Consensus Rating: | Buy (Score: 2.63) |
| Consensus Price Target: | $34.40 (25.00% upside) |
Analysts' Ratings History for Cardiovascular Systems (NASDAQ:CSII)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 9/22/2017 | Raymond James Financial, Inc. | Initiated Coverage | Mkt Perform -> Market Perform | | Low |  |
| 9/21/2017 | Citigroup Inc. | Initiated Coverage | Market Perform | | Low | |
| 7/14/2017 | Needham & Company LLC | Reiterated Rating | Buy | $32.00 -> $37.00 | High | |
| 6/21/2017 | Bank of America Corporation | Downgrade | Neutral -> Underperform | | Low | |
| 1/30/2017 | Lake Street Capital | Initiated Coverage | Buy | $40.00 | N/A | |
| 11/15/2016 | Leerink Swann | Reiterated Rating | Outperform | $30.00 | N/A | |
| 10/27/2016 | Feltl & Co. | Upgrade | Buy -> Strong-Buy | $30.00 | N/A | |
| 10/7/2016 | JMP Securities | Initiated Coverage | Outperform | $35.00 | N/A | |
| 12/23/2015 | Northcoast Research | Initiated Coverage | Buy | $18.00 | N/A | |
| 10/8/2015 | William Blair | Reiterated Rating | Outperform | | N/A | |
| 10/8/2015 | Dougherty & Co | Lower Price Target | Buy | $50.00 -> $32.00 | N/A | |
| 10/8/2015 | Benchmark Co. | Lower Price Target | Buy | $49.00 -> $20.00 | N/A | |
(Data available from 9/25/2015 forward)
Earnings History for Cardiovascular Systems (NASDAQ:CSII)Earnings History by Quarter for Cardiovascular Systems (NASDAQ CSII)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 10/24/2017 | | | | | | | N/A | |
| 8/2/2017 | Q4 2017 | ($0.05) | $0.02 | $51.98 million | $52.90 million | View | Listen | |
| 5/3/2017 | Q3 2017 | ($0.05) | ($0.05) | $51.13 million | $52.10 million | View | Listen | |
| 1/25/2017 | Q217 | ($0.06) | $0.03 | $49.72 million | $50.00 million | View | N/A | |
| 10/26/2016 | Q117 | ($0.18) | ($0.06) | $205.50 million | $49.80 million | View | Listen | |
| 8/3/2016 | Q416 | ($0.20) | ($0.15) | $46.01 million | $48.50 million | View | N/A | |
| 5/4/2016 | Q316 | ($0.54) | ($0.31) | $42.13 million | $44.50 million | View | N/A | |
| 1/21/2016 | Q216 | ($0.50) | ($0.47) | $44.82 million | $41.40 million | View | Listen | |
| 11/4/2015 | Q116 | ($0.42) | ($0.41) | $43.90 million | $43.90 million | View | N/A | |
| 8/5/2015 | Q415 | ($0.30) | ($0.27) | $50.10 million | $48.50 million | View | N/A | |
| 4/29/2015 | Q315 | ($0.33) | ($0.34) | $46.84 million | $47.00 million | View | Listen | |
| 1/28/2015 | Q215 | ($0.34) | ($0.17) | $43.97 million | $44.70 million | View | Listen | |
| 10/29/2014 | Q115 | ($0.33) | ($0.26) | $40.24 million | $41.40 million | View | Listen | |
| 8/6/2014 | Q214 | ($0.28) | ($0.31) | $37.21 million | $39.56 million | View | Listen | |
| 4/30/2014 | Q114 | ($0.32) | ($0.32) | $34.15 million | $34.90 million | View | Listen | |
| 1/29/2014 | Q2 | ($0.34) | ($0.32) | $30.62 million | $32.30 million | View | Listen | |
| 8/7/2013 | Q4 2013 | ($0.30) | ($0.28) | $27.18 million | $28.80 million | View | Listen | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Cardiovascular Systems (NASDAQ:CSII)2017 EPS Consensus Estimate: ($0.45)
2018 EPS Consensus Estimate: $0.11
2019 EPS Consensus Estimate: $0.23
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 4 | ($0.44) | ($0.14) | ($0.26) |
| Q2 2017 | 4 | ($0.26) | ($0.05) | ($0.11) |
| Q3 2017 | 4 | ($0.05) | ($0.02) | ($0.04) |
| Q4 2017 | 4 | ($0.06) | ($0.02) | ($0.04) |
| Q1 2018 | 4 | ($0.08) | $0.00 | ($0.02) |
| Q2 2018 | 4 | ($0.01) | $0.03 | $0.02 |
| Q3 2018 | 3 | $0.04 | $0.05 | $0.04 |
| Q4 2018 | 4 | $0.05 | $0.09 | $0.08 |
| Q1 2019 | 1 | ($0.02) | ($0.02) | ($0.02) |
| Q2 2019 | 1 | $0.04 | $0.04 | $0.04 |
| Q3 2019 | 1 | $0.10 | $0.10 | $0.10 |
| Q4 2019 | 1 | $0.11 | $0.11 | $0.11 |
(Data provided by Zacks Investment Research)
Dividend History for Cardiovascular Systems (NASDAQ:CSII)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Cardiovascular Systems (NASDAQ:CSII)Insider Ownership Percentage: 3.60%
Institutional Ownership Percentage: 74.70%
Insider Trades by Quarter for Cardiovascular Systems (NASDAQ:CSII)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 8/31/2017 | Edward M Brown | Director | Sell | 20,000 | $29.16 | $583,200.00 | |
| 8/30/2017 | Edward M Brown | Director | Sell | 13,031 | $29.09 | $379,071.79 | |
| 8/17/2017 | Laura Gillund | Insider | Sell | 2,350 | $30.42 | $71,487.00 | |
| 8/17/2017 | Scott R Ward | CEO | Sell | 5,529 | $30.41 | $168,136.89 | |
| 8/16/2017 | Alexander Rosenstein | General Counsel | Sell | 979 | $30.71 | $30,065.09 | |
| 8/16/2017 | Kevin J Kenny | COO | Sell | 4,733 | $30.74 | $145,492.42 | |
| 8/16/2017 | Laurence L Betterley | CFO | Sell | 4,443 | $30.74 | $136,577.82 | |
| 5/17/2017 | Alexander Rosenstein | General Counsel | Sell | 219 | $32.30 | $7,073.70 | |
| 11/18/2016 | Alexander Rosenstein | General Counsel | Sell | 529 | $26.80 | $14,177.20 | |
| 11/18/2016 | Edward M Brown | Director | Sell | 10,000 | $26.78 | $267,800.00 | |
| 11/18/2016 | Laura Gillund | Insider | Sell | 1,268 | $26.79 | $33,969.72 | |
| 11/15/2016 | Edward M Brown | Director | Sell | 10,000 | $24.95 | $249,500.00 | |
| 10/10/2016 | Paul A Koehn | SVP | Sell | 30,910 | $25.07 | $774,913.70 | |
| 9/20/2016 | Camber Capital Management Llc | Major Shareholder | Sell | 1,100,000 | $23.26 | $25,586,000.00 | |
| 9/7/2016 | Paul A Koehn | SVP | Sell | 5,969 | $25.02 | $149,344.38 | |
| 8/22/2016 | Alexander Rosenstein | General Counsel | Sell | 234 | $23.82 | $5,573.88 | |
| 8/22/2016 | Kevin J Kenny | COO | Sell | 3,166 | $23.95 | $75,825.70 | |
| 8/22/2016 | Laura Gillund | Insider | Sell | 1,395 | $23.93 | $33,382.35 | |
| 8/22/2016 | Laurence L Betterley | CFO | Sell | 3,568 | $23.96 | $85,489.28 | |
| 8/22/2016 | Paul A Koehn | SVP | Sell | 2,527 | $23.92 | $60,445.84 | |
| 8/17/2016 | Paul A Koehn | SVP | Sell | 4,000 | $22.17 | $88,680.00 | |
| 2/26/2016 | Paul A Koehn | SVP | Sell | 956 | $38.79 | $37,083.24 | |
| 2/23/2016 | Camber Capital Management Llc | Major Shareholder | Buy | 250,000 | $7.55 | $1,887,500.00 | |
| 1/25/2016 | Scott R Ward | CEO | Buy | 2,700 | $9.30 | $25,110.00 | |
| 10/2/2015 | Robert J. Thatcher | insider | Sell | 64,700 | $16.31 | $1,055,257.00 | |
| 9/2/2015 | David Martin | CEO | Sell | 19,646 | $23.81 | $467,771.26 | |
| 9/1/2015 | Kevin J Kenny | COO | Sell | 5,289 | $23.85 | $126,142.65 | |
| 9/1/2015 | Laurence L Betterley | CFO | Sell | 9,597 | $23.96 | $229,944.12 | |
| 9/1/2015 | Paul A Koehn | SVP | Sell | 4,946 | $23.86 | $118,011.56 | |
| 9/1/2015 | Robert J Thatcher | Insider | Sell | 5,282 | $23.85 | $125,975.70 | |
| 8/18/2015 | David Martin | CEO | Sell | 17,688 | $23.99 | $424,335.12 | |
| 8/18/2015 | Kevin J. Kenny | COO | Sell | 3,913 | $24.00 | $93,912.00 | |
| 8/18/2015 | Laurence L Betterley | CFO | Sell | 8,476 | $24.00 | $203,424.00 | |
| 8/18/2015 | Paul A. Koehn | SVP | Sell | 4,402 | $23.99 | $105,603.98 | |
| 8/18/2015 | Robert J. Thatcher | insider | Sell | 2,960 | $23.99 | $71,010.40 | |
| 8/12/2015 | Brent G Blackey | Director | Buy | 2,500 | $22.74 | $56,850.00 | |
| 5/28/2015 | Paul A Koehn | SVP | Sell | 4,389 | $27.86 | $122,277.54 | |
| 5/1/2015 | Brent G Blackey | Director | Buy | 2,500 | $29.38 | $73,450.00 | |
| 2/10/2015 | David Martin | CEO | Sell | 7,500 | $35.85 | $268,875.00 | |
| 2/5/2015 | David Martin | CEO | Sell | 4,500 | $34.96 | $157,320.00 | |
| 1/29/2015 | Kevin J Kenny | VP | Sell | 4,212 | $35.00 | $147,420.00 | |
| 9/3/2014 | David Martin | CEO | Sell | 10,248 | $28.85 | $295,654.80 | |
| 9/3/2014 | Kevin J Kenny | VP | Sell | 3,528 | $28.85 | $101,782.80 | |
| 9/3/2014 | Laurence L Betterley | CFO | Sell | 4,674 | $28.82 | $134,704.68 | |
| 9/3/2014 | Paul A Koehn | SVP | Sell | 2,612 | $28.85 | $75,356.20 | |
| 9/3/2014 | Robert J Thatcher | Insider | Sell | 2,791 | $28.85 | $80,520.35 | |
| 8/28/2014 | Paul A Koehn | SVP | Sell | 1,315 | $28.82 | $37,898.30 | |
| 8/22/2014 | David Martin | CEO | Sell | 13,957 | $29.03 | $405,171.71 | |
| 8/22/2014 | Kevin J Kenny | VP | Sell | 2,914 | $29.09 | $84,768.26 | |
| 8/22/2014 | Laurence L Betterley | CFO | Sell | 6,578 | $29.02 | $190,893.56 | |
| 8/22/2014 | Paul A Koehn | SVP | Sell | 2,755 | $29.06 | $80,060.30 | |
| 8/22/2014 | Robert J Thatcher | Insider | Sell | 3,225 | $29.06 | $93,718.50 | |
| 8/19/2014 | David Martin | CEO | Sell | 11,754 | $29.28 | $344,157.12 | |
| 8/19/2014 | Kevin J Kenny | VP | Sell | 2,117 | $29.28 | $61,985.76 | |
| 8/19/2014 | Laurence L Betterley | CFO | Sell | 5,725 | $29.28 | $167,628.00 | |
| 8/19/2014 | Paul A Koehn | SVP | Sell | 2,168 | $29.28 | $63,479.04 | |
| 8/19/2014 | Robert J Thatcher | Insider | Sell | 2,537 | $29.28 | $74,283.36 | |
| 7/16/2014 | David Martin | CEO | Sell | 10,703 | $28.83 | $308,567.49 | |
| 7/16/2014 | Kevin J Kenny | VP | Sell | 3,007 | $28.83 | $86,691.81 | |
| 7/16/2014 | Laurence L Betterley | CFO | Sell | 3,984 | $28.83 | $114,858.72 | |
| 7/16/2014 | Paul A Koehn | SVP | Sell | 2,716 | $28.83 | $78,302.28 | |
| 7/16/2014 | Robert J Thatcher | Insider | Sell | 2,939 | $28.83 | $84,731.37 | |
| 4/25/2014 | Kevin Kenny | VP | Sell | 15,484 | $28.79 | $445,784.36 | |
| 2/24/2014 | David Martin | CEO | Sell | 29,200 | $37.31 | $1,089,452.00 | |
| 2/20/2014 | Kevin Kenny | VP | Sell | 6,779 | $36.02 | $244,179.58 | |
| 1/30/2014 | David Martin | CEO | Sell | 50,000 | $35.12 | $1,756,000.00 | |
| 1/30/2014 | Robert Thatcher | VP | Sell | 35,139 | $35.06 | $1,231,973.34 | |
| 11/22/2013 | Robert Thatcher | VP | Sell | 22,384 | $32.82 | $734,642.88 | |
| 10/31/2013 | James E Flaherty | Insider | Sell | 34,819 | $30.35 | $1,056,756.65 | |
| 10/23/2013 | David Martin | CEO | Sell | 154,080 | $27.73 | $4,272,638.40 | |
| 10/23/2013 | James E Flaherty | Insider | Sell | 36,682 | $26.85 | $984,911.70 | |
| 10/23/2013 | Robert J Thatcher | VP | Sell | 23,426 | $28.19 | $660,378.94 | |
| 10/22/2013 | Kevin J Kenny | VP | Sell | 5,608 | $27.31 | $153,154.48 | |
| 10/16/2013 | Kevin J Kenny | VP | Sell | 4,182 | $22.95 | $95,976.90 | |
| 10/14/2013 | David Martin | CEO | Sell | 21,170 | $22.00 | $465,740.00 | |
| 9/20/2013 | David Martin | CEO | Sell | 6,702 | $20.24 | $135,648.48 | |
| 9/20/2013 | James Flaherty | Insider | Sell | 2,066 | $20.28 | $41,898.48 | |
| 9/20/2013 | Robert Thatcher | VP | Sell | 1,274 | $20.28 | $25,836.72 | |
| 9/19/2013 | Laurence Betterley | CFO | Sell | 2,694 | $20.32 | $54,742.08 | |
| 9/19/2013 | Paul Koehn | SVP | Sell | 1,094 | $20.32 | $22,230.08 | |
| 9/18/2013 | David Martin | CEO | Sell | 8,030 | $20.94 | $168,148.20 | |
| 9/18/2013 | James Flaherty | Insider | Sell | 2,970 | $20.94 | $62,191.80 | |
| 9/18/2013 | Laurence Betterley | CFO | Sell | 4,324 | $20.93 | $90,501.32 | |
| 9/18/2013 | Paul Koehn | SVP | Sell | 1,732 | $20.93 | $36,250.76 | |
| 9/18/2013 | Robert Thatcher | VP | Sell | 1,731 | $20.94 | $36,247.14 | |
| 9/10/2013 | John Friedman | Director | Sell | 48,273 | $20.73 | $1,000,699.29 | |
| 8/30/2013 | David Martin | CEO | Sell | 21,552 | $20.64 | $444,833.28 | |
| 8/30/2013 | James Flaherty | Insider | Sell | 7,165 | $20.64 | $147,885.60 | |
| 8/30/2013 | Kevin Kenny | VP | Sell | 1,899 | $20.64 | $39,195.36 | |
| 8/30/2013 | Laurence Betterley | CFO | Sell | 8,692 | $20.64 | $179,402.88 | |
| 8/27/2013 | David Martin | CEO | Sell | 27,229 | $21.07 | $573,715.03 | |
| 8/27/2013 | James Flaherty | Insider | Sell | 9,051 | $21.07 | $190,704.57 | |
| 8/27/2013 | Kevin Kenny | VP | Sell | 2,396 | $21.07 | $50,483.72 | |
| 8/27/2013 | Laurence Betterley | CFO | Sell | 10,982 | $21.07 | $231,390.74 | |
| 8/16/2013 | James Flaherty | Insider | Sell | 1,255 | $20.51 | $25,740.05 | |
| 8/16/2013 | Laurence Betterley | CFO | Sell | 1,568 | $20.51 | $32,159.68 | |
| 8/14/2013 | James Flaherty | Insider | Sell | 4,902 | $21.31 | $104,461.62 | |
| 8/13/2013 | Kevin Kenny | VP | Sell | 2,529 | $21.20 | $53,614.80 | |
| 8/8/2013 | James Flaherty | Insider | Sell | 19,649 | $22.27 | $437,583.23 | |
| 7/30/2013 | David Martin | CEO | Sell | 11,094 | $19.69 | $218,440.86 | |
| 7/30/2013 | Laurence L Betterley | CFO | Sell | 6,579 | $19.72 | $129,737.88 | |
| 7/30/2013 | Robert J Thatcher | VP | Sell | 3,112 | $19.86 | $61,804.32 | |
| 6/3/2013 | James E Flaherty | Insider | Sell | 10,000 | $21.00 | $210,000.00 | |
| 5/31/2013 | Paul A Koehn | VP | Sell | 2,472 | $20.00 | $49,440.00 | |
| 5/28/2013 | Kevin J Kenny | VP | Sell | 4,182 | $19.95 | $83,430.90 | |
| 5/20/2013 | Glen D Nelson | Director | Buy | 10,250 | $18.47 | $189,317.50 | |
| 5/16/2013 | Glen D Nelson | Director | Buy | 4,753 | $18.93 | $89,974.29 | |
| 5/13/2013 | Glen D Nelson | Director | Buy | 18,393 | $18.11 | $333,097.23 | |
| 11/13/2012 | Glen D Nelson | Director | Buy | 33,000 | $11.96 | $394,680.00 | |
| 8/23/2012 | David Martin | CEO | Sell | 10,510 | $9.07 | $95,325.70 | |
| 8/23/2012 | James E Flaherty | Insider | Sell | 4,018 | $9.07 | $36,443.26 | |
| 8/23/2012 | Laurence L Betterley | CFO | Sell | 4,770 | $9.07 | $43,263.90 | |
| 8/23/2012 | Paul A Koehn | VP | Sell | 2,496 | $9.07 | $22,638.72 | |
(Data available from 1/1/2013 forward)
Headline Trends for Cardiovascular Systems (NASDAQ:CSII)
Latest Headlines for Cardiovascular Systems (NASDAQ:CSII)
| Source: |
|
| Date | Headline |
|---|
 | Cardiovascular Systems, Inc. (CSII) Receives New Coverage from Analysts at Raymond James Financial, Inc.
www.americanbankingnews.com - September 22 at 9:18 AM |
| Cardiovascular Systems, Inc. (CSII) Earns Market Perform Rating from Analysts at Citigroup Inc.
www.americanbankingnews.com - September 21 at 5:38 PM |
| Leerink Swann Equities Analysts Lower Earnings Estimates for Cardiovascular Systems, Inc. (CSII)
www.americanbankingnews.com - September 20 at 9:22 AM |
 | Will Hurricanes Choke Cardiovascular (CSII) Q1 Performance? - Nasdaq
www.nasdaq.com - September 19 at 5:35 PM |
| Cardiovascular Systems, Inc. (CSII) Forecasted to Post Q2 2018 Earnings of ($0.01) Per Share
www.americanbankingnews.com - September 19 at 9:24 AM |
 | Cardiovascular Systems Announces Anticipated Revenue Impact ... - Business Wire (press release)
www.businesswire.com - September 18 at 10:36 PM |
 | Cardiovascular Systems suffers a hurricane hangover
www.bizjournals.com - September 18 at 5:34 PM |
 | CSII Crosses Below Key Moving Average Level
www.thestreet.com - September 18 at 5:34 PM |
| Commit To Purchase Cardiovascular Systems At $25, Earn 10.4% Annualized Using Options
www.nasdaq.com - September 14 at 6:25 PM |
 | Cardiovascular Systems (CSII) Presents At Lake Street Capital Best Ideas Growth Conference - Slideshow
seekingalpha.com - September 14 at 6:25 PM |
| Cardiovascular Systems (CSII) Down 3.5% Since Earnings Report: Can It Rebound? - Nasdaq
www.nasdaq.com - September 9 at 5:14 PM |
 | Cardiovascular Systems (CSII) Down 3.5% Since Earnings Report: Can It Rebound?
finance.yahoo.com - September 8 at 5:59 PM |
| Cardiovascular Systems (CSII) Catches Eye: Stock Jumps 6.9%
finance.yahoo.com - September 5 at 7:10 PM |
| Cardiovascular Systems, Inc. breached its 50 day moving average in a Bullish Manner : CSII-US : September 5, 2017
finance.yahoo.com - September 5 at 7:10 PM |
| $53.41 Million in Sales Expected for Cardiovascular Systems, Inc. (CSII) This Quarter
www.americanbankingnews.com - September 5 at 1:56 AM |
| Zacks: Analysts Anticipate Cardiovascular Systems, Inc. (CSII) Will Post Earnings of -$0.07 Per Share
www.americanbankingnews.com - September 3 at 8:28 PM |
| Cardiovascular Systems, Inc. (CSII) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - September 2 at 4:40 AM |
| Edward M. Brown Sells 13,031 Shares of Cardiovascular Systems, Inc. (CSII) Stock
www.americanbankingnews.com - September 1 at 7:42 PM |
| Edward M. Brown Sells 20,000 Shares of Cardiovascular Systems, Inc. (CSII) Stock
www.americanbankingnews.com - September 1 at 7:40 PM |
| ETFs with exposure to Cardiovascular Systems, Inc. : August 31, 2017
finance.yahoo.com - August 31 at 10:32 PM |
| Cardiovascular Systems, Inc. :CSII-US: Earnings Analysis: 2017 By the Numbers : August 28, 2017
finance.yahoo.com - August 28 at 5:24 PM |
| Notable Two Hundred Day Moving Average Cross - CSII
www.nasdaq.com - August 25 at 9:43 PM |
| Cardiovascular Systems (CSII) Presents At CFA Society Of Minnesota 6th Annual Intellisight Conference - Slideshow
seekingalpha.com - August 23 at 7:11 PM |
| Haeggquist & Eck Investigates Cardiovascular Systems Inc. for ... - Business Wire (press release)
www.businesswire.com - August 22 at 11:11 PM |
| Haeggquist & Eck Investigates Cardiovascular Systems Inc. for Paying Illegal Kickbacks, Promoting Its Devices for Off-Label Purposes, and Violating FDA Laws and Regulations
finance.yahoo.com - August 22 at 11:11 PM |
| Cardiovascular Systems, Inc. (CSII) Insider Laura Gillund Sells 2,350 Shares
www.americanbankingnews.com - August 21 at 8:10 PM |
| Cardiovascular Systems, Inc. (CSII) CEO Sells $168,136.89 in Stock
www.americanbankingnews.com - August 21 at 7:46 PM |
| Cardiovascular Systems, Inc. (CSII) Downgraded to "Strong Sell" at BidaskClub
www.americanbankingnews.com - August 19 at 12:24 PM |
| Cardiovascular Systems, Inc. (CSII) Expected to Post Quarterly Sales of $53.41 Million
www.americanbankingnews.com - August 18 at 3:30 PM |
| Insider Selling: Cardiovascular Systems, Inc. (CSII) General Counsel Sells 979 Shares of Stock
www.americanbankingnews.com - August 17 at 8:52 PM |
| Insider Selling: Cardiovascular Systems, Inc. (CSII) CFO Sells 4,443 Shares of Stock
www.americanbankingnews.com - August 17 at 8:32 PM |
| Insider Selling: Cardiovascular Systems, Inc. (CSII) COO Sells 4,733 Shares of Stock
www.americanbankingnews.com - August 17 at 8:32 PM |
| Cardiovascular Systems Unveils Favorable LIBERTY 360 Data
finance.yahoo.com - August 15 at 6:18 PM |
| Cardiovascular Systems, Inc. – Value Analysis (NASDAQ:CSII) : August 15, 2017
finance.yahoo.com - August 15 at 6:18 PM |
| LIBERTY 360° Study 12-Month Sub-Analysis Reveals High Freedom from Major Amputation and Major Adverse Events ... - Business Wire (press release)
www.businesswire.com - August 12 at 5:01 PM |
| LIBERTY 360° Study 12-Month Sub-Analysis Reveals High Freedom from Major Amputation and Major Adverse Events (MAE) Using Cardiovascular Systems’ Diamondback 360 ...
www.businesswire.com - August 10 at 6:49 PM |
| A new sub-analysis from the landmark LIBERTY 360° study, sponsored by Cardiovascular Systems, Inc.
www.thestreet.com - August 10 at 6:49 PM |
| LIBERTY 360° Study 12-Month Data Demonstrate Lasting Benefits Following Endovascular Intervention in Patients with Critical Limb Ischemia (CLI)
finance.yahoo.com - August 10 at 6:49 PM |
| LIBERTY 360° Study 12-Month Sub-Analysis Reveals High Freedom from Major Amputation and Major Adverse Events (MAE) Using Cardiovascular Systems’ Diamondback 360® Peripheral Orbital Atherectomy System (OAS)
finance.yahoo.com - August 10 at 6:48 PM |
| Cardiovascular Systems, Inc. (NASDAQ:CSII) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - August 8 at 7:34 AM |
| Equities Analysts Issue Forecasts for Cardiovascular Systems, Inc.'s Q1 2018 Earnings (NASDAQ:CSII)
www.americanbankingnews.com - August 7 at 7:58 AM |
| Cardiovascular Systems, Inc. (CSII) Cut to "Sell" at Zacks Investment Research
www.americanbankingnews.com - August 6 at 5:44 PM |
| Northcoast Research Weighs in on Cardiovascular Systems, Inc.'s FY2018 Earnings (CSII)
www.americanbankingnews.com - August 4 at 6:02 PM |
| Q2 2018 Earnings Estimate for Cardiovascular Systems, Inc. (CSII) Issued By Leerink Swann
www.americanbankingnews.com - August 4 at 4:54 PM |
| Cardiovascular Systems' (CSII) CEO Scott Ward on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 4 at 12:00 AM |
| Cardiovascular Systems, Inc. (NASDAQ:CSII) Announces Quarterly Earnings Results
www.americanbankingnews.com - August 3 at 8:32 PM |
| Edited Transcript of CSII earnings conference call or presentation 2-Aug-17 8:45pm GMT
finance.yahoo.com - August 3 at 6:59 PM |
| Cardiovascular Systems, Inc. breached its 50 day moving average in a Bearish Manner : CSII-US : August 2, 2017
finance.yahoo.com - August 2 at 11:24 PM |
| Cardiovascular Systems beats 4Q profit forecasts
finance.yahoo.com - August 2 at 11:24 PM |
| Cardiovascular Systems, Inc. Reports Fiscal 2017 Fourth-Quarter Financial Results - Business Wire (press release)
www.businesswire.com - August 2 at 6:21 PM |
Cardiovascular Systems (CSII) Chart for Monday, September, 25, 2017
